STOCKHOLM, Oct. 18, 2021 /PRNewswire/ — Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has through its fully owned subsidiary Mentice Inc entered into an agreement with ABBOTT Inc. to provide simulation solutions for training of interventional devices. The order covers systems that will be offered […]
Other News
BIOMODEX Launches Synthetic Clot Product for Neurovascular Training
Biomodex to debut Thrombotech™ at CNS 2021 Annual Meeting in Austin, TX BOSTON, Oct. 18, 2021 /PRNewswire/ — BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, has announced the launch of Thrombotech™, a new hydrogel-based synthetic clot product that can be used for neurovascular training using EVIAS Plus™ – […]
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System in Pulmonary Embolism Patients
IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing […]
CLEERLY APPOINTS JIM HARTMAN AS CHIEF REVENUE OFFICER
Sales strategy expert brings industry success to leverage growth. NEW YORK – October 18, 2021 – Cleerly, the company creating a new standard of care for heart disease, announced today it has appointed Jim Hartman as Chief Revenue Officer. In this role, Jim will be responsible for driving the company’s […]
FEops HEARTguide Authorized by FDA for Unprecedented LAAo Planning Capabilities
GENT, Belgium–(BUSINESS WIRE)–FEops today announced that it received De Novo authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device*. FEops HEARTguide™ will enable physicians to virtually model clinical scenarios with different implant positions and sizes […]
OneProjects Announces $17 Million in New Financing to Advance Development of 4D Cardiac Imaging Technology
DUBLIN & MUNICH–(BUSINESS WIRE)–OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million. The Series A2 financing was led by imec.xpand, with participation from the European […]
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Oct. 14, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support […]
Abcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
LOS ANGELES, Oct. 14, 2021 /PRNewswire/ — Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. Dr. Davidson is currently CEO of New Amsterdam Pharma, and was previously the founding CEO and Chief Medical Officer of Corvidia Therapeutics, which was acquired by Novo-Nordisk in 2020. He also co-founded […]
HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial
Trial to evaluate new technology that may help physicians prevent heart attacks in patients REDWOOD CITY, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque […]
PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx’s VAZALORE Specifically Indicated for Secondary Prevention
Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke SPARTA, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective […]



